Medical Minute Series: Experts Perspectives on New Advances in HER2-Mutated NSCLC

Through this series of Medical Minutes with accompanying slides, take home knowledge of current molecular testing and treatment recommendations for patients with HER2-mutated NSCLC and increase your awareness of the latest research on emerging therapies including wild-type EGFR-sparing HER2 tyrosine kinase inhibitors to address ongoing therapeutic needs in this patient population.

Share

Program Content

Activities

NSCLC HER2 Alterations Testing
Medical Minute 1: HER2 Alterations and Testing in NSCLC
Video
Congratulations: You achieved a completion on 04/09/2022

Released: October 17, 2024

Expires: April 16, 2025

NSCLC HER2 Alterations Therapies
Medical Minute 2: Current and Emerging Therapies for Advanced NSCLC With HER2 Mutations and HER2 Overexpression
Video
Congratulations: You achieved a completion on 04/09/2022

Released: October 18, 2024

Expires: April 17, 2025

Activities

NSCLC HER2 Alterations Testing
Medical Minute 1: HER2 Alterations and Testing in NSCLC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 16, 2024

Expires: October 15, 2025

NSCLC HER2 Alterations Therapies
Medical Minute 2: Current and Emerging Therapies for Advanced NSCLC With HER2 Mutations and HER2 Overexpression
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 17, 2024

Expires: October 16, 2025

Activities

Emerging HER2 Selective  TKIs
Emerging HER2-Selective TKIs for HER2-Mutated NSCLC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 12, 2024

Expires: November 11, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.